Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs).

The study met its primary endpoint of ACR20 response and key secondary endpoints at Week 24, demonstrating a statistically significant improvement with zemprocitinib versus placebo (p...